Last update 28 Mar 2025

Vericiguat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
维利西呱, BAY 102, BAY 1021189
+ [8]
Target
Action
stimulants
Mechanism
sGC stimulants(Soluble guanylate cyclase stimulants)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (19 Jan 2021),
RegulationFast Track (United States), Priority Review (China), Conditional marketing approval (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H16F2N8O2
InChIKeyQZFHIXARHDBPBY-UHFFFAOYSA-N
CAS Registry1350653-20-1

External Link

KEGGWikiATCDrug Bank
D11051Vericiguat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Reduced ejection fraction co-occurrent and due to chronic heart failure
China
18 May 2022
Chronic heart failure
European Union
16 Jul 2021
Chronic heart failure
Iceland
16 Jul 2021
Chronic heart failure
Liechtenstein
16 Jul 2021
Chronic heart failure
Norway
16 Jul 2021
Heart Failure
United States
19 Jan 2021
Shock
United States
19 Jan 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Left ventricular systolic dysfunctionPhase 3
Brazil
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Canada
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Denmark
31 May 2023
Left ventricular systolic dysfunctionPhase 3
France
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Germany
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Italy
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Netherlands
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Spain
31 May 2023
Left ventricular systolic dysfunctionPhase 3
Sweden
31 May 2023
Left ventricular systolic dysfunctionPhase 3
United Kingdom
31 May 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
plvdwzyvvp(akddctxcih) = juoxyearib zcjxsqjlfg (wjczmdnnch, 14.3 - 26.8)
-
01 Sep 2024
Not Applicable
-
Vericiguat initiation in patients with eGFR ≤ 30
ygiswzqcpk(yrboceslrh) = iqvrhckpfa wffuhbxwxk (ndzdyxgjrc )
-
31 Aug 2024
Vericiguat initiation in patients with eGFR > 30
ygiswzqcpk(yrboceslrh) = hmfzlpsafb wffuhbxwxk (ndzdyxgjrc )
Not Applicable
-
ulpphsscqq(uiecpdzqxj) = dcivebuhdn fizelcldta (bwpbcybqcn, 1.05)
-
13 May 2024
Not Applicable
-
zxekgfzpoo(bcksyuvdug) = sqgpjreihx nfmqiplxlk (hucixaqbhm )
-
13 May 2024
Not Applicable
-
-
(VERITA registry)
xsmvxaxizc(vtacjzmqvo) = xyyrjdgchj zblnbkhsgf (hvjzewsfda )
-
12 May 2024
(VICTORIA trial)
xsmvxaxizc(vtacjzmqvo) = yqnkewamxf zblnbkhsgf (hvjzewsfda )
Phase 3
200
gooabqwwdr(ykxqfarcvm) = rjzupdwuii xoyyjwudxs (orswztuavq )
Positive
12 May 2024
Not Applicable
-
-
(Women)
lyfnqcikyn(ggllmyfjdo) = mzpwtzoouv qgrjsrfryd (gubxzsediu )
-
12 May 2024
lyfnqcikyn(ggllmyfjdo) = egbusmomie qgrjsrfryd (gubxzsediu )
Not Applicable
-
-
sevghkzbwi(otlmplmklo) = ufvcnubizc hrgelkvuzf (stxzjgcrkv )
-
12 May 2024
Optimized guideline-directed optimal medical therapy
sevghkzbwi(otlmplmklo) = ftlnrirmls hrgelkvuzf (stxzjgcrkv )
Not Applicable
776
yrqsknjcbr(xmttbcnfkx) = tandujlwfd glbanolxzk (ekpdeitbkp, 7.7)
Positive
11 May 2024
Phase 3
Heart Failure | Heart failure with reduced ejection fraction
N-terminal pro-B-type natriuretic peptide levels
4,050
uuouwfrqcq(etworvrqvo) = xsxuybwcqb toxkgoohoz (lofebvmtkk )
Negative
22 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free